68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
NCT02174679 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-07-27
Summary
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Conditions
- Carcinoid Cancer
- Neuroendocrine Tumors
- Medullary Thyroid Cancer
- Cancers Expressing Somatostatin Receptors
Interventions
- DRUG
-
68Ga DOTATATE
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
Sponsors & Collaborators
-
Jonsson Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Johannes Czernin, MD · University of California, Los Angeles
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
NCT02038738 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
NCT02359500 ·Status: TERMINATED ·Phase: PHASE1
-
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
NCT03271281 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
NCT02810600 ·Status: COMPLETED
-
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
NCT03001349 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
NCT01967537 ·Status: COMPLETED ·Phase: PHASE2
-
DOTATOC PET/CT for Imaging NET Patients
NCT03583528 ·Status: ACTIVE_NOT_RECRUITING
-
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
NCT01747096 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
NCT03145857 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
NCT01980732 ·Status: NO_LONGER_AVAILABLE
-
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
NCT02358018 ·Status: NO_LONGER_AVAILABLE
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
NCT01879657 ·Status: COMPLETED ·Phase: NA
-
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
NCT04041882 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
NCT01869725 ·Status: COMPLETED ·Phase: PHASE2
-
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
NCT02840149 ·Status: COMPLETED ·Phase: PHASE3
-
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
NCT04888481 ·Status: RECRUITING ·Phase: PHASE2
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
NCT04804371 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
NCT01619865 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors
NCT00569738 ·Status: UNKNOWN
-
68Ga-DOTA-TATE PET/CT Imaging in NETs
NCT04847505 ·Status: RECRUITING ·Phase: PHASE3
-
[68 Ga]-DOTANOC PET/CT in GEP-NETs
NCT02608203 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
[68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
NCT05898854 ·Status: COMPLETED ·Phase: PHASE2
-
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
NCT02375464 ·Status: NO_LONGER_AVAILABLE